Approval · Notice of Compliance 24643 · 2020
AZARGA: Notice of Compliance 24643
Issued November 18, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24643
- Date
- November 18, 2020
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add a new adverse reaction of hallucination to the product monograph, in the post-marketing adverse drug reactions section based on post marketing spontaneous case reports and literature cases
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZARGA | 02331624 | Marketed |
Medicinal ingredients
- TIMOLOL MALEATE 0.5 PER
- BRINZOLAMIDE 1 PER